Evaluation of a new generation of oral contraceptives.

摘要: Ortho Pharmaceutical Corporations Advisory Board for the New Progestins has reviewed about 100 reports of comparative and noncomparative clinical studies published since 1980 to compare safety efficacy metabolic effects oral contraceptives (OCs) containing no more than 35 mcg ethinyl estradiol new progestins desogestrel gestodene or norgestimate. Researchers in many collected data a rather short period so their analyses could not clearly determine relevance. Small sample size methodologic differences between made it difficult true Nevertheless progestin OCs may have advantage over existing mainly because are linked with decline androgenicity. The each OC essentially equals that other (0-1 pregnancy/100 woman years exposure). progestin-containing similar cycle control as OCs. Their 6- 12-month continuation rates tend be higher cause minor on coagulation thus inducing relatively low thrombotic risk nonsmokers. They do affect carbohydrate metabolism much low-dose do. effect decreased androgenicity positive lipid indicating they protect against cardiovascular disease. need conduct larger epidemiologic follow-up randomized controlled trials describe elucidate among